(Albany, USA) DelveInsight’s ‘RNA Therapies Competitive Landscape 2025‘ report provides comprehensive global coverage of available, marketed, and pipeline RNA therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space and future growth potential of the RNA therapies competitive domain.
With over 80 key companies active in the RNA therapies space, the market is projected to grow due to advancements in mRNA, siRNA, and antisense oligonucleotide-based therapies. Emerging RNA-based, especially in areas like oncology, infectious diseases, and genetic disorders, are fueling this expansion.
Request for sample report @ RNA Therapies clinical trials report
Key Takeaways from the RNA Therapies Pipeline Report
Request a sample and discover the recent advances in the RNA therapies market @ RNA Therapies Competitive Landscape Report
RNA Therapies Overview
RNA therapies represent a rapidly evolving field in biotechnology, offering innovative treatment approaches for a wide range of diseases. These therapies utilize RNA molecules to regulate gene expression, modify protein production, or replace faulty genetic instructions. The main types of RNA-based therapeutics include messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides (ASOs), and RNA aptamers.
mRNA therapies, exemplified by COVID-19 vaccines, instruct cells to produce specific proteins that trigger immune responses or treat genetic disorders. siRNA and miRNA therapies silence harmful genes by interfering with messenger RNA, making them promising for neurodegenerative diseases, cancers, and rare genetic disorders. ASOs function by binding to target RNA sequences to modulate gene expression, while RNA aptamers act as targeted inhibitors or delivery agents.
Advancements in delivery technologies, including lipid nanoparticles and conjugation strategies, have improved the stability and effectiveness of RNA-based drugs. Regulatory approvals for RNA therapies, such as those for spinal muscular atrophy (SMA) and hereditary transthyretin amyloidosis, have validated their therapeutic potential.
With ongoing research into optimizing stability, specificity, and safety, RNA therapies hold promise for revolutionizing personalized medicine, oncology, infectious diseases, and rare genetic disorders, paving the way for the next generation of precision therapeutics.
RNA Therapies Pipeline Analysis: Drug Profile
LEQVIO: Novartis
LEQVIO (inclisiran) is an injectable treatment given every six months to reduce low-density lipoprotein (LDL) cholesterol, often referred to as “bad” cholesterol. It is a small interfering RNA (siRNA) therapy that targets a liver protein called PCSK9 (proprotein convertase subtilisin kexin type 9), which normally limits the number of receptors that remove LDL cholesterol from the bloodstream. By blocking the translation of PCSK9 mRNA, LEQVIO decreases PCSK9 production, helping to lower LDL cholesterol levels. It is used alongside diet and statins to manage high LDL cholesterol in adults with elevated cholesterol or atherosclerosis. Novartis holds the global rights to develop, produce, and market LEQVIO through a partnership with Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapies.
Find out more about FDA RNA therapies @ RNA Therapies Analysis
RNA Therapies Market Dynamics
The RNA therapies market has seen rapid growth and significant interest in recent years, driven largely by advances in biotechnology, increasing investments in the development of novel therapies, and the success of mRNA vaccines during the COVID-19 pandemic. With the potential to treat genetic disorders, cancers, infectious diseases, and other conditions that were previously considered untreatable, the RNA therapy market is expected to expand rapidly.
One of the key drivers of the market is the increasing prevalence of chronic and rare genetic diseases. RNA therapies are particularly effective in treating rare genetic disorders by correcting or modulating the expression of specific genes. For instance, the approval of treatments like SPINRAZA (for spinal muscular atrophy) and ONPATTRO (for hereditary transthyretin-mediated amyloidosis) has validated the commercial viability and therapeutic impact of RNA-based drugs. Additionally, RNA therapeutics provide a promising approach for precision medicine, where treatments can be tailored to the genetic profile of an individual patient.
On the competitive front, the RNA therapy market is dominated by both established pharmaceutical companies and emerging biotech startups. Major pharmaceutical players such as Moderna, Alnylam Pharmaceuticals, and BioNTech have made significant strides in developing RNA therapies and are investing heavily in expanding their pipelines. This competitive landscape is further enriched by partnerships and collaborations between biotech companies and academic institutions, which are accelerating innovation and product development. However, challenges such as delivery mechanisms, safety concerns, and scalability of RNA-based therapies still remain critical hurdles that industry players need to address.
Regulatory advancements and supportive government policies also contribute to the market’s positive outlook. Regulatory agencies like the FDA and EMA have shown a willingness to fast-track the approval of RNA-based treatments, particularly for life-threatening or rare diseases with limited treatment options. The success of mRNA vaccines has also built confidence in the safety and efficacy of RNA therapeutics, paving the way for a more streamlined regulatory process for future RNA-based drugs.
To know more about RNA therapies, visit @ RNA Therapies Market Insights
A snapshot of the pipeline RNA therapies mentioned in the report:
Discover more about RNA therapies in clinical development @ RNA Therapies in Clinical Trials
Key Developments in the RNA Therapies Domain
Scope of the RNA Therapies Competitive Landscape Report
Table of Contents
1. RNA Therapies Pipeline Report Introduction
2. RNA Therapies Pipeline Report Executive Summary
3. RNA Therapies Pipeline: Overview
4. RNA Therapies Marketed Drugs
4.1. LEQVIO: Novartis
5. RNA Therapies Clinical Trial Therapeutics
6. RNA Therapies Pipeline: Late-Stage Products (Pre-registration)
7. RNA Therapies Pipeline: Late-Stage Products (Phase III)
7.1. ARO-APOC3: Arrowhead Pharmaceuticals
8. RNA Therapies Pipeline: Mid-Stage Products (Phase II)
8.1. AB-729: Arbutus Biopharm
9. RNA Therapies Pipeline: Early-Stage Products (Phase I/II)
9.1. ARO-C3: Arrowhead Pharmaceuticals
10. RNA Therapies Pipeline: Preclinical and Discovery Stage Products
10.1. SGB-9768: SanegeneBio
11. RNA Therapies Pipeline Therapeutics Assessment
12. Inactive Products in the RNA Therapies Pipeline
13. Company-University Collaborations (Licensing/Partnering) Analysis
14. Unmet Needs
15. RNA Therapies Market Drivers and Barriers
16. Appendix
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/asco-conference-coverage
